-
Late-Breaking Real-World Experience of People Switching from Obeticholic Acid to Livdelzi® to be Presented at The Liver Meeting® 2025
-
New Three-Year Interim Data Demonstrates Livdelzi® May Help Stabilize or Improve Liver Health in PBC Patients
October 23, 2025--FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with liver disease at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), November 7-11 in Washington, D.C. Key findings from more than 35 accepted abstracts across PBC and viral hepatitis will include late-breaking data and three oral presentations.
Primary Biliary Cholangitis Research
Three late-breaking presentations will share new data on Livdelzi® (seladelpar) in people living with primary biliary cholangitis (PBC), including real-world treatment experience following the withdrawal of obeticholic acid (LB#5037), liver stiffness outcomes from a three-year interim analysis of the ongoing ASSURE study (LB#5031), and long-term pruritus data from the RESPONSE trial and its open-label extension (#LB5015). These studies explore how Livdelzi is being used in clinical practice, its potential impact on liver health, and patient-reported experiences with itch over time.
“The data we’re sharing at The Liver Meeting® reflect our continued dedication to advancing science that meaningfully improves the lives of people affected by liver disease,” said Anu Osinusi, Vice President, Clinical Research for Hepatitis, Respiratory and Emerging Viruses at Gilead. “These interim long-term findings in PBC deepen our understanding of disease progression and highlight the potential to help improve patients’ liver health and symptoms.”
Viral Hepatitis Research
Gilead also plans to share new data from across its viral hepatitis portfolio. In hepatitis delta virus (HDV), Gilead will present integrated analyses from the MYR204 (NCT03852433) and MYR301 (NCT03852719) studies, investigating the long-term safety and efficacy of bulevirtide for the treatment of chronic HDV. Gilead will also present an analysis from the Phase 3 ALLIANCE study (NCT03547908) that aims to study HIV/HBV co-infected participants who achieved hepatitis B virus surface antigen (HBsAg) loss, a marker of HBV functional cure, after starting tenofovir-based treatments. Lastly, data from a Phase 1b study on the safety, tolerability and antiviral efficacy of GS-2829 and GS-6779, novel investigational therapeutic HBV vaccines, among virally suppressed participants with chronic hepatitis B, will be presented.
Gilead Commitment to Advocacy
At The Liver Meeting® 2025, Gilead will launch Reflecting Realities™, a campaign dedicated to capturing the emotions and real experiences of people living with liver conditions. Reflecting Realities™ brings together two campaigns: “BehinD the SilenCe” in collaboration with the World Hepatitis Alliance (WHA) and All the Feelings with PBC™ in collaboration with the PBC Foundation and Friends of the PBC Foundation. “BehinD the SilenCe” highlights the experiences of people living with viral hepatitis and will feature portrait photographs of people living with viral hepatitis and audio testimonials of their lived experience. These campaigns aim to showcase the real impact of liver disease and facilitate more meaningful conversations between people living with liver disease and their healthcare providers.
Additionally, Gilead will announce which independent emerging investigators Gilead has selected to participate in its Research Scholars Program in PBC. The objective of the program is to support innovative research that aims to close scientific knowledge gaps and address unmet medical needs.
For more information, including a complete list of abstract titles being presented at the meeting, please visit the AASLD website.
About Livdelzi
Livdelzi® is an oral PPAR-delta agonist, or delpar, for the treatment of PBC. PPAR-delta has been shown to regulate critical metabolic and liver disease pathways. Preclinical and clinical data indicate Livdelzi has anticholestatic, anti-inflammatory, antipruritic, and antifibrotic effects.
About Gilead Sciences in Liver Disease
For decades, Gilead has pioneered the way forward to improve the lives of people living with liver disease around the world. The company has helped to transform hepatitis C from a chronic condition into a curable condition. For individuals living with hepatitis B or hepatitis delta, Gilead's focus on advancing medicines drives hope that today’s research will turn into tomorrow’s cures. Beyond viral hepatitis, Gilead is working to deliver advanced treatments for people living with PBC. The commitment of Gilead does not stop there. Through ground-breaking science and collaborative partnerships, the company strives to create healthier futures for everyone living with liver disease. Gilead remains devoted to a future without liver disease.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.